{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:44:11Z","timestamp":1793983451449,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T00:00:00Z","timestamp":1553990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jfma.2019.03.018","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T10:39:28Z","timestamp":1555411168000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"P1","title":["The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"119","author":[{"given":"Yi-No","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chu","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hwan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hui","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.03.018_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jfma.2019.03.018_bib2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(05)66995-4","article-title":"Marfan's syndrome","volume":"366","author":"Ho","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2019.03.018_bib3","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(05)67789-6","article-title":"Marfan's syndrome","volume":"366","author":"Judge","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2019.03.018_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrcardio.2010.31","article-title":"Marfan syndrome. Part 2: treatment and management of patients","volume":"7","author":"Canadas","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib5","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1161\/CIRCULATIONAHA.107.693523","article-title":"Medical management of Marfan syndrome","volume":"117","author":"Keane","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2019.03.018_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.03.018_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jfma.2019.03.018_bib8","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.03.018_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1358863X15569868","article-title":"Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome","volume":"20","author":"Bhatt","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.jfma.2019.03.018_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","article-title":"Losartan added to \u03b2-blockade therapy for aortic root dilation in marfan syndrome: a randomized, open-label pilot study","volume":"88","author":"Chiu","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jfma.2019.03.018_bib11","first-page":"A6845","article-title":"Effect of losartan treatment on aortic dilatation in adults with Marfan syndrome","volume":"158","author":"Franken","year":"2014","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.jfma.2019.03.018_bib12","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2019.03.018_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","article-title":"Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial","volume":"37","author":"Forteza","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2019.03.018_bib14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ahj.2013.02.019","article-title":"Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy","volume":"165","author":"Lacro","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jfma.2019.03.018_bib15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan's syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.03.018_bib16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2019.03.018_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/00015385.2017.1314134","article-title":"Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial","volume":"72","author":"Muino-Mosquera","year":"2017","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijcard.2014.11.082","article-title":"A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes","volume":"179","author":"Sandor","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.amjcard.2013.06.019","article-title":"Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome","volume":"112","author":"Pees","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jfma.2019.03.018_bib21","series-title":"Review manager (RevMan) [computer program]. Version 5.3. Copenhagen","year":"2014"},{"key":"10.1016\/j.jfma.2019.03.018_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-8703(97)70248-5","article-title":"Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome","volume":"133","author":"Haouzi","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.jfma.2019.03.018_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpeds.2006.09.003","article-title":"Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome","volume":"150","author":"Selamet Tierney","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jfma.2019.03.018_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.200608167","article-title":"Fibrillin-1 regulates the bioavailability of TGFbeta1","volume":"176","author":"Chaudhry","year":"2007","journal-title":"J Cell Biol"},{"issue":"1 Suppl","key":"10.1016\/j.jfma.2019.03.018_bib27","first-page":"I365","article-title":"Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome","volume":"114","author":"Ikonomidis","year":"2006","journal-title":"Circulation"},{"issue":"1 Suppl","key":"10.1016\/j.jfma.2019.03.018_bib28","first-page":"I371","article-title":"Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm","volume":"114","author":"Nataatmadja","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2019.03.018_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cge.12436","article-title":"Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes","volume":"87","author":"Cook","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.jfma.2019.03.018_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCGENETICS.114.000950","article-title":"Beneficial outcome of losartan therapy depends on type of FBN1 mutation in marfan syndrome","volume":"8","author":"Franken","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jfma.2019.03.018_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijcard.2016.04.186","article-title":"The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials","volume":"217","author":"Gao","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2019.03.018_bib32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.298.13.1539","article-title":"Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial","volume":"298","author":"Ahimastos","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jfma.2019.03.018_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","article-title":"Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism","volume":"332","author":"Habashi","year":"2011","journal-title":"Science"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618306697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618306697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:41:03Z","timestamp":1760539263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664618306697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0929664618306697"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.03.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}